Action Pharma A/S is a Holte, Denmark-based biotech developing novel drug candidates that target melanocortin receptors. Its lead candidate, AP214, is being developed to protect against acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. The company focuses on advancing programs to clinical proof of concept for subsequent partnering. It completed a €5m financing round from existing shareholders including Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital. The new capital will be used to advance ongoing phase 2a studies and to initiate a phase 2b study of AP214. Interim phase 2a efficacy and safety data were expected by the end of June 2010.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2010